Neurocrine Biosciences Reclaims Identity in neurocrine.buzz Dispute

Neurocrine Biosciences, Inc. successfully initiated a UDRP proceeding against Jonen Boteda to address the unauthorized registration of <neurocrine.buzz>. The Complainant, a prominent biopharmaceutical company specializing in neurological and endocrine-related diseases, argued that the domain is an identical match to its established trademark. The filing emphasized that the Respondent has no affiliation with the company and registered the domain to exploit the global reputation of a brand that has been active in the medical sector for decades.

Rationale for the Transfer Order

I. The domain <neurocrine.buzz> incorporates the Complainant’s trademark in its entirety, creating a situation where internet users are likely to mistake the site for an official company resource.
II. The Respondent holds no trademark registrations, licenses, or permissions that would justify the use of this specific brand name in a digital address.
III. Given the specialized nature of the Complainant’s work and its long-standing market presence, it is highly improbable that the Respondent selected the name without prior knowledge of the pharmaceutical company.
IV. Registering a domain that mirrors a famous corporate name without providing a legitimate service or critique suggests an intent to divert web traffic or profit from the brand’s accumulated goodwill.

Evidence of Intentional Misuse

The circumstances surrounding the registration indicate that the Respondent aimed to leverage the distinctiveness of the Neurocrine name. By choosing a generic top-level domain like “.buzz,” the registrant created a platform that could easily be used for disseminating unofficial information or hosting deceptive content. The failure of the Respondent to provide any evidence of a legitimate business plan or a personal connection to the name further supported the necessity of a transfer.

Safeguarding Corporate Reputation in New TLDs

This case highlights the ongoing necessity for brands to monitor the expanding landscape of domain extensions. In the pharmaceutical and biotech industries, where precision and trust are paramount, allowing third parties to hold brand-identical domains creates significant exposure to reputational harm. The successful recovery of this domain underscores that trademark protections extend across all extensions, regardless of whether they are traditional or modern gTLDs.
If you are dealing with unauthorized registrations that threaten your intellectual property, the ClaimOn team is ready to help you execute a recovery plan to secure your digital footprint and protect your brand’s integrity.